Safety and Efficacy of APD356 in the Treatment of Obesity
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c
receptor agonist, in clinical development as a potential treatment for obesity.
The purpose of this study is to obtain a preliminary assessment of the safety and efficacy of
APD356, when administered daily for 12 weeks, in obese subjects who are otherwise healthy.
Subjects who are on concomitant medications for control of hypertension or blood lipids may
qualify.